Hennion & Walsh Asset Management’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $447K | Sell |
3,253
-6,952
| -68% | -$956K | 0.02% | 707 |
|
|
2025
Q1 | $1.84M | Sell |
10,205
-3,473
| -25% | -$626K | 0.08% | 295 |
|
|
2024
Q4 | $2.14M | Sell |
13,678
-232
| -2% | -$36.3K | 0.1% | 272 |
|
|
2024
Q3 | $2.53M | Sell |
13,910
-7,740
| -36% | -$1.41M | 0.12% | 220 |
|
|
2024
Q2 | $3.98M | Sell |
21,650
-11,504
| -35% | -$2.11M | 0.2% | 117 |
|
|
2024
Q1 | $5.9M | Buy |
33,154
+1,756
| +6% | +$312K | 0.32% | 62 |
|
|
2023
Q4 | $3.9M | Sell |
31,398
-19,423
| -38% | -$2.41M | 0.22% | 110 |
|
|
2023
Q3 | $5.9M | Buy |
50,821
+1,139
| +2% | +$132K | 0.38% | 45 |
|
|
2023
Q2 | $5.83M | Buy |
49,682
+4,447
| +10% | +$522K | 0.35% | 62 |
|
|
2023
Q1 | $3.62M | Buy |
45,235
+32
| +0.1% | +$2.56K | 0.22% | 118 |
|
|
2022
Q4 | $3.58M | Buy |
45,203
+4,547
| +11% | +$360K | 0.22% | 116 |
|
|
2022
Q3 | $2.83M | Buy |
40,656
+7,663
| +23% | +$534K | 0.19% | 144 |
|
|
2022
Q2 | $2.17M | Buy |
32,993
+9,625
| +41% | +$632K | 0.13% | 191 |
|
|
2022
Q1 | $1.56M | Buy |
23,368
+9,231
| +65% | +$614K | 0.08% | 257 |
|
|
2021
Q4 | $989K | Buy |
+14,137
| New | +$989K | 0.05% | 360 |
|